Association of cetuximab with adverse pulmonary events in cancer patients: A comprehensive review

Journal of Experimental and Clinical Cancer Research

Volumn 28, Issue 1, 2009, Pages

  Hoag, Jeffrey B ^a,b   Azizi, Aimel ^b   Doherty, Timothy J ^b   Lu, Jason ^b   Willis, Rudolph E ^a   Lund, Mark E ^a,b  

^a CANCER TREATMENT CENTERS OF AMERICA   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLOUROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COUGHING; DYSPNEA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; HYPOXEMIA; HYPOXIA; INJECTION SITE REACTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG DISEASE; LUNG EMBOLISM; LUNG INFECTION; LUNG INSUFFICIENCY; LUNG NON SMALL CELL CANCER; NASOPHARYNX CANCER; OVARY CANCER; PANCREAS CANCER; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SEPSIS; SIDE EFFECT; SKIN CANCER; SPUTUM LEVEL; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; WHEEZING; DRUG EFFECT; LUNG; NEOPLASM; PATHOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LUNG; NEOPLASMS;

EID: 69549138343     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-28-113     Document Type: Article

References (61)

1. Biopharmaceutical benchmarks 2006. G Walsh, Nat Biotechnology 2006 24 769 776 10.1038/nbt0706-769 (Pubitemid 44086612)
2. Safety-related regulatory actions for biologicals approved in the United States and the European Union. T Giezen A Mantel-Teeuwisse S Straus H Schellekens H Leufkens A Egberts, JAMA 2008 300 1887 1896 10.1001/jama.300.16. 1887 18940975
3. Erbitux (Cetuximab) Package Insert. Inclone Syetems Incorporated NYN, Bristol-Myers Squibb Co PN, 2008
4. ErbB receptors: from oncogenes to targeted cancer therapies. H Zhang A Berezov Q Wang G Zhang J Drebin R Murali M Greene, Journal Clinical Investigation 2007 117 2051 2058 10.1172/JCI32278 (Pubitemid 47224766)
5. Randomized pahse II study of cetuximab plus cisplatin/vinorelbine compasred with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small cell lung cancer. R Rosell G Robinet A Szczesna R Ramlau M Costenla B Mennecier W Pfiefer K O'Bryne T Welte R Kolb R Pirker A Chemaissani M Perol M Ranson P Ellis K Pilz M Reck, Ann Oncology 2008 19 362 369 10.1093/annonc/mdm474 (Pubitemid 351201721)
6. Clinical management of cutaneous toxicity of anti-EGFR agents. M Monti S Motta, Int J Biol Markers 2007 22 S53 S61 17520582
7. Incidence and management of cutaneous toxicities associated with cetuximab. MW Saif R Kim, Expert Opin Drug Saf 2007 6 175 182 10.1517/14740338.6.2.175 17367263 (Pubitemid 46380811)
8. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. L Leard B Cho K Jones S Hays W Tope J Golden C Hoopes, J Heart Lung Transplant 2007 26 1340 1344 10.1016/j.healun.2007.09.019 18096489 (Pubitemid 350256993)
9. Cetuximab-associated infusion reactions: pathology and Management. D Patel R Goldberg, Oncology 2006 20 1373 1382 17112000
10. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. D Arnold T Hohler C Dittrich F Lordick T Seufferlein J Riemann E Woll T Herrmann A Zubel H Schmoll, Ann Oncology 2008 19 1442 1449 10.1093/annonc/mdn150
11. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. A Asnacios L Fartoux O Romano C Tesmoingt SS Louafi T Mansoubakht P Artru T Poynard O Rosmorduc M Hebbar J Taieb, Cancer 2008 112 2733 2739 10.1002/cncr.23489 18412149 (Pubitemid 351969218)
12. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Baselga JM Trigo J Bourhis J Tortochaux H Cortes-Funes R Hitt P Gascon N Amellal A Harstrick A Eckardt, J Clin Oncol 2005 23 5568 5577 10.1200/JCO.2005.07.119 16009950 (Pubitemid 46300151)
13. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur D Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky KK Ang, N Engl J Med 2006 354 567 578 10.1056/NEJMoa053422 16467544 (Pubitemid 43209104)
14. Adding cetuximab to capecitabine plus oxaliplatin (XELOX)in first-line treatment of metastatic colorectal cancer: a rnadomized phase II trial of the Swiss Group for Clinical Research SAKK. M Bornr D Koeberle R Von Moos P Saletti D Rauch V Hess A Trojan D Helbling B Pestalozzi C Caspar T Ruhstaller A Roth A Kappeler D Dietrich D Lanz W Mingrone Swiss Group for Clinical Cancer Research (SAKK) BS, Ann Oncology 2008 19 1288 1289 10.1093/annonc/mdn058 (Pubitemid 351911959)
15. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Bourhis F Rivera R Mesia A Awada L Geoffrois C Borel Y Humblet A Lopez-Pousa R Hitt ME Vega Villegas L Duck D Rosine N Amellal A Schueler A Harstrick, J Clin Oncol 2006 24 2866 2872 10.1200/JCO.2005.04.3547 16717293 (Pubitemid 46630587)
16. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. B Burtness MA Goldwasser W Flood B Mattar AA Forastiere, J Clin Oncol 2005 23 8646 8654 10.1200/JCO.2005.02.4646 16314626 (Pubitemid 46211507)
17. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. CA Butts D Bodkin EL Middleman CW Englund D Ellison Y Alam H Kreisman P Graze J Maher HJ Ross PM Ellis W McNulty E Kaplan V Pautret MR Weber FA Shepherd, J Clin Oncol 2007 25 5777 5784 10.1200/JCO.2007.13.0856 18089875
18. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. S Cascinu R Berardi R Labianca S Siena A Falcone E Aitini S Barni CF Di E Dapretto G Tonini C Pierantoni S Artale S Rota I Floriani M Scartozzi A Zaniboni, Lancet Oncol 2008 9 39 44 10.1016/S1470-2045(07)70383-2 18077217
19. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. AT Chan MM Hsu BC Goh EP Hui TW Liu MJ Millward RL Hong J Whang-Peng BB Ma KF To M Mueser N Amellal X Lin AY Chang, J Clin Oncol 2005 23 3568 3576 10.1200/JCO.2005.02.147 15809453 (Pubitemid 46243502)
20. Cetuximab monotherapy and Cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. D Cunningham Y Humblet S Siena D Khayat H Blieberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem, New England Journal of Medicine 2004 351 337 345 10.1056/NEJMoa033025 15269313 (Pubitemid 38944402)
21. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. T Gamucci F Nelli G Cianci G Grassi L Moscetti I Sperduti M Zeuli E Cortesi G D'Auria C Pollera, Clinical Colorectal Cancer 2008 7 273 279 10.3816/CCC.2008.n.035 18650196
22. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience. V Gebbia S Del Prete N Borsellino F Ferrau P Tralongo F Verderame V Leonardi E Capasso E Maiello R Bordonaro S Stinco B Agostara C Barone, Clinical Colorectal Cancer 2006 5 422 428 10.3816/CCC.2006.n.013 16635281
23. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. N Hanna R Lilenbaum R Ansari T Lynch R Govindan PA Janne P Bonomi, J Clin Oncol 2006 24 5253 5258 10.1200/JCO.2006.08.2263 17114658 (Pubitemid 46631370)
24. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. RS Herbst M Arquette DM Shin K Dicke EE Vokes N Azarnia WK Hong MS Kies, J Clin Oncol 2005 23 5578 5587 10.1200/JCO.2005.07.120 16009949 (Pubitemid 46300152)
25. Phase I trial cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. R Hofheinz K Horisberger C Woernle F Wenz U Kraus-Tiefenbacher G Kahler D Dinter R Grobholz S Heeger S Post A Hochhaus F Willeke, Int Journal Radiation Oncology Biol Phys 2006 66 1384 1390 10.1016/j.ijrobp.2006.07.005 (Pubitemid 44778934)
26. Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. E Ibrahim A Zeeneldin A Al-Gahmi Y Sallam E Fawzi Y Bahadur, Indian J Cancer 2007 44 56 61 10.4103/0019-509X.35812 17938482
27. Cetuximab for the treatment of colorectal cancer. D Jonker C O'Callaghan C Karapetis J Zalcberg D Tu H Au S Berry M Krahn T Price R Simes N Tebbutt G van Hazel R Wierzbicki C Langer M Moore, New England Journal of Medicine 2007 357 2040 2048 10.1056/NEJMoa071834 18003960 (Pubitemid 350106711)
28. A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. J Konner RJ Schilder FA DeRosa SR Gerst WP Tew PJ Sabbatini ML Hensley DR Spriggs CA Aghajanian, Gynecol Oncol 2008 110 140 145 10.1016/j.ygyno.2008. 04.018 18554700
29. A phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. D Koo J Lee T Kim H Chang M Ryu S Lee M Kim S Sym J Lee Y Kang, J Korean Med Sci 2007 22 S98 S103 10.3346/jkms.2007.22.S.S98 17923763
30. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. H Lenz E Van Cutsem S Khambata-Ford R Mayer P Gold P Stella B Mirtsching A Cohn A Pippas N Azarnia Z Tsuchihashi D Mauro E Rowinsky, J Clinical Oncology 2006 24 4914 4921 10.1200/JCO.2006.06.7595 (Pubitemid 46630920)
31. Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. JP Machiels C Sempoux P Scalliet JC Coche Y Humblet CE Van J Kerger JL Canon M Peeters S Aydin S Laurent A Kartheuser B Coster S Roels JF Daisne B Honhon L Duck C Kirkove MA Bonny K Haustermans, Ann Oncol 2007 18 738 744 10.1093/annonc/mdl460 17208931 (Pubitemid 46523279)
32. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. P Martin-Martorell S Rosello E Rodriguez-Braun I Chirivella A Bosch A Cervantes, Br J Cancer 2008 99 455 458 10.1038/sj.bjc. 6604530 18665167
33. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. S Modi G D'Andrea L Norton TJ Yao J Caravelli PP Rosen C Hudis AD Seidman, Clin Breast Cancer 2006 7 270 277 10.3816/CBC.2006.n.040 16942645
34. Cetuximab with hepatic arterial infusion of chemotherapy for the treatment of colorectal cancer liver metastases. B Neyns M Aerts NY Van C Fontaine CL De D Schallier J Vanderauwera MF De F Vandenbroucke H Everaert V Meert MJ De RM De G Delvaux GJ De, Anticancer Res 2008 28 2459 2467 18751435
35. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. B Paule MO Herelle E Rage M Ducreux R Adam C Guettier MP Bralet, Oncology 2007 72 105 110 10.1159/000111117 18025804 (Pubitemid 350249137)
36. First-line single-agent cetuximab in patients with advanced colorectal cancer. A Pessino S Artale S Sciallero A Guglielmi G Fornarini IC Andreotti S Mammoliti D Comandini F Caprioni E Bennicelli V Andretta S Siena A Sobrero, Ann Oncol 2008 19 711 716 10.1093/annonc/mdm516 18073221
37. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. DG Pfister YB Su DH Kraus SL Wolden E Lis TB Aliff AJ Zahalsky S Lake MN Needle AR Shaha JP Shah MJ Zelefsky, J Clin Oncol 2006 24 1072 1078 10.1200/JCO.2004.00.1792 16505426 (Pubitemid 46638804)
38. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). C Pinto FF DI S Siena S Cascinu FL Rojas Llimpe C Ceccarelli V Mutri L Giannetta S Giaquinta C Funaioli R Berardi C Longobardi E Piana AA Martoni, Ann Oncol 2007 18 510 517 10.1093/annonc/mdl459 17164226 (Pubitemid 46359631)
39. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. F Robert MP Ezekiel SA Spencer RF Meredith JA Bonner MB Khazaeli MN Saleh D Carey AF LoBuglio RH Wheeler MR Cooper HW Waksal, J Clin Oncol 2001 19 3234 3243 11432891
40. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. F Robert G Blumenschein RS Herbst FV Fossella J Tseng MN Saleh M Needle, J Clin Oncol 2005 23 9089 9096 10.1200/JCO.2004.00.1438 16301597 (Pubitemid 46264008)
41. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. C Rodel D Arnold M Hipp T Liersch K Dellas I Iesalnieks RM Hermann F Lordick A Hinke W Hohenberger R Sauer, Int J Radiat Oncol Biol Phys 2008 70 1081 1086 17881150
42. Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity. H Safran M Suntharalingam T Dipetrillo T Ng LA Doyle M Krasna A Plette D Evans H Wanebo P Akerman J Spector N Kennedy T Kennedy, Int J Radiat Oncol Biol Phys 2008 70 391 395 17980508
43. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. LB Saltz NJ Meropol PJ Loehrer Sr MN Needle J Kopit RJ Mayer, J Clin Oncol 2004 22 1201 1208 10.1200/JCO.2004.10.182 14993230 (Pubitemid 41079832)
44. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. AA Secord JA Blessing DK Armstrong WH Rodgers Z Miner MN Barnes G Lewandowski RS Mannel, Gynecol Oncol 2008 108 493 499 10.1016/j.ygyno.2007.11.029 18191993
45. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. AF Sobrero J Maurel L Fehrenbacher W Scheithauer YA Abubakr MP Lutz ME Vega-Villegas C Eng EU Steinhauer J Prausova HJ Lenz C Borg G Middleton H Kroning G Luppi O Kisker A Zubel C Langer J Kopit HA Burris III, J Clin Oncol 2008 26 2311 2319 10.1200/JCO.2007.13.1193 18390971
46. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. J Souglakos A Kalykaki L Vamvakas N Androulakis K Kalbakis S Agelaki N Vardakis M Tzardi AP Kotsakis J Gioulbasanis D Tsetis G Sfakiotaki D Chatzidaki D Mavroudis V Georgoulias, Ann Oncol 2007 18 305 310 10.1093/annonc/mdl392 17079693 (Pubitemid 46323098)
47. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Tabernero CE Van E az-Rubio A Cervantes Y Humblet T Andre JL Van Laethem P Soulie E Casado C Verslype JS Valera G Tortora F Ciardiello O Kisker GA de, J Clin Oncol 2007 25 5225 5232 10.1200/JCO.2007.13.2183 18024868 (Pubitemid 350232254)
48. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. CD Thienelt PA Bunn Jr N Hanna A Rosenberg MN Needle ME Long DL Gustafson K Kelly, J Clin Oncol 2005 23 8786 8793 10.1200/JCO.2005.03.1997 16246975 (Pubitemid 46211524)
49. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. J Tol M Koopman CJ Rodenburg A Cats GJ Creemers JG Schrama FL Erdkamp AH Vos L Mol NF Antonini CJ Punt, Ann Oncol 2008 19 734 738 10.1093/annonc/ mdm607 18272912
50. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. JB Vermorken J Trigo R Hitt P Koralewski E az-Rubio F Rolland R Knecht N Amellal A Schueler J Baselga, J Clin Oncol 2007 25 2171 2177 10.1200/JCO.2006.06.7447 17538161 (Pubitemid 46954639)
51. Platinum-based chemotherapy plus cetuximab in head and neck cancer. JB Vermorken R Mesia F Rivera E Remenar A Kawecki S Rottey J Erfan D Zabolotnyy HR Kienzer D Cupissol F Peyrade M Benasso I Vynnychenko RD De C Bokemeyer A Schueler N Amellal R Hitt, N Engl J Med 2008 359 1116 1127 10.1056/NEJMoa0802656 18784101
52. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. B Vincenzi D Santini C Rabitti R Coppola ZB Beomonte L Trodella G Tonini, Br J Cancer 2006 94 792 797 10.1038/sj.bjc.6603018 16508634
53. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. HQ Xiong A Rosenberg A LoBuglio W Schmidt RA Wolff J Deutsch M Needle JL Abbruzzese, J Clin Oncol 2004 22 2610 2616 10.1200/JCO.2004.12.040 15226328 (Pubitemid 41103748)
54. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. AX Zhu K Stuart LS Blaszkowsky A Muzikansky DP Reitberg JW Clark PC Enzinger P Bhargava JA Meyerhardt K Horgan CS Fuchs DP Ryan, Cancer 2007 110 581 589 10.1002/cncr.22829 17583545
55. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. C Gridelli A Morabito V Gebbia M Mencoboni F Carrozza MG Vigano C Verusio R Bollina R Mattioli MR Valerio G Valmadre P Maione A Rossi T Cascone F Morgillo MM Di MC Piccirillo C Gallo F Perrone F Ciardiello, Lung Cancer 2009
56. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. S Hughes J Liong A Miah S Ahmad M Leslie P Harper J Prendiville J Shamash R Subramaniam A Gaya J Spicer D Landau, J Thorac Oncol 2008 3 648 651 10.1097/JTO.0b013e3181757a60 18520806 (Pubitemid 351787311)
57. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. CP Belani MT Schreeder RG Steis RA Guidice TA Marsland EH Butler SS Ramalingam, Cancer 2008 113 2512 2517 10.1002/cncr.23902 18816622
58. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. R Pirker JR Pereira A Szczesna PJ von M Krzakowski R Ramlau I Vynnychenko K Park CT Yu V Ganul JK Roh E Bajetta K O'Byrne MF de W Eberhardt T Goddemeier M Emig U Gatzemeier, Lancet 2009 373 1525 1531 10.1016/S0140-6736(09)60569-9 19410716
59. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. DM Shin NJ Donato R Perez-Soler HJ Shin JY Wu P Zhang K Lawhorn FR Khuri BS Glisson J Myers G Clayman D Pfister J Falcey H Waksal J Mendelsohn WK Hong, Clin Cancer Res 2001 7 1204 1213 11350885
60. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Baselga D Pfister MR Cooper R Cohen B Burtness M Bos G D'Andrea A Seidman L Norton K Gunnett J Falcey V Anderson H Waksal J Mendelsohn, J Clin Oncol 2000 18 904 914 10673534
61. Radiation-Induced Ling Disease and the impact of Radiation Methods in Imaging Features. K Park F Chung M Chun F Suh, RadioGraphics 2000 20 983 998